Drug intelligence / Profile preview

Lucentra

Development stage: Unknown
Lead developer: Espad Pharmed
Administration: Intracutaneous, Subcutaneous, Dermal

Overview

Lucentra is a hyaluronic acid-based dermal filler developed and manufactured by Espad Pharmed. It is designed for aesthetic and cosmetic applications, including soft-tissue augmentation, facial volumization, and the correction of facial wrinkles and folds. Administered via dermal, subcutaneous, or intracutaneous injection, Lucentra utilizes cross-linked hyaluronic acid to provide immediate structural support and volume by physically occupying space and attracting water molecules within the skin's extracellular matrix. It is primarily used in the field of aesthetic medicine to enhance facial contours and reduce the appearance of aging.

Brand names: Lucentra

Beyond the preview

Go deeper on Lucentra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lucentra.

Explore the full profile